Literature DB >> 10528137

Structural determinants of phorbol ester binding in synaptosomes: pharmacokinetics and pharmacodynamics.

T V Murphy1, C Prountzos, P Kotsonis, L Iannazzo, H Majewski.   

Abstract

The present study used structurally distinct phorbol esters to investigate the relationship between their pharmacokinetics of binding to protein kinase C (PKC) in rat brain cortex synaptosomes, their affinity for PKC in synaptosomes and ability to enhance noradrenaline release from rat brain cortex. Affinity binding studies using [3deoxyphorbol 13-tetradecanoate (dPT)=PDB&z. Gt;12-deoxyphorbol 13-acetate (dPA)=phorbol 12,13-diacetate (PDA). In intact synaptosomes PDB, dPA and PDA rapidly displaced bound [3H]PDB whereas PMA and dPT were comparatively slow. However, the displacement rates for all the phorbol esters were equally rapid in synaptosomal membranes or synaptosomes permeabilised with Staphylococcus alpha-toxin. These results suggest that the lipophilic phorbol esters (dPT and PMA) are slower to displace [3H]PDB binding because they are hindered by the plasma membrane. In brain cortex slices it was found that the rate of displacement of [3H]PDB binding was closely correlated with the degree of elevation of transmitter noradrenaline release. Thus kinetic characteristics may determine biological responses and this may be particularly evident in events which occur rapidly or where there is fast counter-regulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528137     DOI: 10.1016/s0014-2999(99)00540-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Differential abilities of phorbol esters in inducing protein kinase C (PKC) down-regulation in noradrenergic neurones.

Authors:  P Kotsonis; L Funk; C Prountzos; L Iannazzo; H Majewski
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Etomidate reduces glutamate uptake in rat cultured glial cells: involvement of PKA.

Authors:  M Räth; K J Föhr; H U Weigt; A Gauss; J Engele; M Georgieff; S Köster; O Adolph
Journal:  Br J Pharmacol       Date:  2008-08-18       Impact factor: 8.739

Review 3.  Wealth of opportunity - the C1 domain as a target for drug development.

Authors:  P M Blumberg; N Kedei; N E Lewin; D Yang; G Czifra; Y Pu; M L Peach; V E Marquez
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

4.  Investigation of the inhibitory effects of HA-1077 and Y-32885 on the translocation of PKCbetaI, PKCbetaII and PKCzeta in human neutrophils.

Authors:  X Siomboing; B Gressier; T Dine; C Brunet; M Luyckx; M Cazin; J C Cazin
Journal:  Mediators Inflamm       Date:  2001-12       Impact factor: 4.711

5.  Variability in content of the anti-AIDS drug candidate prostratin in Samoan populations of Homalanthus nutans.

Authors:  Holly E Johnson; Sandra A Banack; Paul Alan Cox
Journal:  J Nat Prod       Date:  2008-12       Impact factor: 4.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.